New CONNECT Study Presents data on Measures of Cognitive Performance in Adult
Patients Treated with Brintellix® (vortioxetine) for Major Depressive Disorder
Takeda and Lundbeck to Present Late-breaker at International College of
Neuropsychopharmacology World Congress
VANCOUVER, British Columbia, June 16, 2014
VANCOUVER, British Columbia, June 16, 2014 /PRNewswire/ --Takeda
Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today
announced results from CONNECT, a new study that evaluated the effect of
Brintellix 10-20 mg/d on aspects of cognitive function, using an objective
neuropsychological test (the Digit Symbol Substitution Test or DSST)
associated with executive function, processing speed and attention, in adults
with major depressive disorder (MDD). The data will be presented as a
late-breaker poster at the 29^th International College of
Neuropsychopharmacology (CINP) World Congress in Vancouver, Canada.
In this study, adult patients with MDD, a MADRS total score >/= 26, and
self-reported cognitive dysfunction were randomized to flexibly dosed
Brintellix 10-20 mg/d (n=198), placebo (n=194), or the active reference
(duloxetine 60 mg/d; n=210) included to demonstrate assay sensitivity for
depression. The primary endpoint was change from baseline to Week 8 on the
DSST (ANCOVA). Key secondary endpoints, patient-reported Perceived Deficits
Questionnaire (PDQ) attention/concentration and planning/organization subscore
and the Clinical Global Impressions – Global Improvement Scale (CGI-I) at Week
8 were analyzed in a pre-specified testing sequence using the full-analysis
set (FAS) and a mixed-effects model repeated measures (MMRM) approach.
Additional endpoints included MADRS total score to confirm efficacy on the
overall symptoms of depression, and a prespecified path analysis to detect
direct vs. indirect effects on cognition.
"Symptoms of impaired cognitive function, which include a diminished ability
to think, concentrate or make decisions, can be common for people with MDD,
and this area is in need of further investigation," said John Zajecka, M.D.,
Associate Professor of Psychiatry at Rush University Medical Center and study
investigator. "These study results are encouraging and while further
investigation is warranted, they are similar to previous published clinical
trial data for Brintellix on aspects of cognitive function in patients with
Brintellix was statistically superior to placebo on the primary endpoint of
change from baseline to week 8 on the DSST (p<0.05) and two key secondary
endpoints – PDQ (p<0.01) and CGI-I (p<0.05). Brintellix was statistically
superior to placebo on the MADRS (p<0.05) change from baseline at week eight.
In the study, a pre-specified path-analysis to detect direct vs. indirect
effects of treatment on cognition indicated Brintellix's effect on cognitive
performance was primarily a direct treatment effect rather than due to
alleviation of overall depressive symptoms. Assay sensitivity for the
treatment of depression, determined by mean change from baseline to week 8 in
MADRS total score versus placebo, was confirmed in this trial by the active
reference duloxetine. In this study, common adverse events (>5%) for
Brintellix were nausea, headache, and diarrhea.
The U.S. Food and Drug Administration approved Brintellix on September 30,
2013 for the treatment of MDD in adults.
Patients can visit www.Brintellix.com to sign up for additional information
about this new treatment option.
About Brintellix (vortioxetine)
The mechanism of the antidepressant effect of Brintellix is not fully
understood. It is an inhibitor of serotonin (5-HT) reuptake and that is
thought to be a mechanism of its action. It is also an agonist at 5-HT1A
receptors, a partial agonist at 5-HT1B receptors and an antagonist at 5-HT3,
5-HT1D and 5-HT7 receptors. The contribution of each of these activities to
Brintellix's antidepressant effect has not been established. It is considered
to be the first and only compound with this combination of pharmacodynamic
activity. The clinical relevance of this is unknown.
Brintellix was discovered by Lundbeck researchers in Copenhagen, Denmark. The
clinical trial program in the U.S. was conducted jointly by Lundbeck and
Takeda, and Takeda holds the new drug application for the U.S. market.
Brintellix is a trademark of H. Lundbeck A/S and is used under license by
Takeda Pharmaceuticals America, Inc.
The World Health Organization has issued an Anatomical Therapeutic Chemical
(ATC) code for Brintellix that places it in the category of "Other"
The most commonly observed adverse events in MDD patients treated with
Brintellix in 6-8 week placebo-controlled studies (incidence greater than or
equal to 5 percent and at least twice the rate of placebo) were nausea,
constipation and vomiting. Overall, 5 to 8 percent of the patients who
received Brintellix 5 to 20 mg/day in short-term trials discontinued treatment
due to an adverse reaction, the most common being nausea, compared with 4
percent of placebo-treated patients in these studies. Brintellix and other
antidepressants may cause serious side effects. See Important Safety
In clinical studies, Brintellix had no significant effect on body weight as
measured by the mean change from baseline in 6-8 week placebo-controlled
studies. In the 6-month, double-blind, placebo-controlled phase of a long-term
study in patients who had responded to Brintellix during the initial 12-week,
open-label phase, there was no significant effect on body weight between
Brintellix and placebo-treated patients. Brintellix has not been associated
with any clinically significant effects on vital signs, including systolic and
diastolic blood pressure and heart rate, as measured in placebo-controlled
The recommended starting dose of Brintellix is 10 mg once daily without regard
to meals. The dose should then be increased to 20 mg/day, as tolerated,
because higher doses demonstrated better treatment effects in trials conducted
in the U.S. A dose decrease down to 5 mg/day may be considered for patients
who do not tolerate higher doses. The available doses provide important
flexibility for physicians to help address the variability of patient needs.
Brintellix is available as 5 mg, 10 mg and 20 mg tablets.
IMPORTANT SAFETY INFORMATION
Suicidal Thoughts or Actions
Antidepressants may increase suicidal thoughts or actions in some children,
teens or young adults within the first few months of treatment or when the
dose is changed. Depression or other serious mental illnesses are the most
important causes of suicidal thoughts or actions. People who have (or have a
family history of) bipolar illness, or suicidal thoughts or actions may have a
particularly high risk. Pay close attention to any changes, especially sudden
changes in mood, behavior, thoughts or feelings. Call your healthcare provider
right away if symptoms such as anxiety, irritability, impulsivity, trouble
sleeping, aggressive behavior or suicidal thoughts are new, worse or worry
you. BRINTELLIX has not been evaluated for use in patients under 18.
Do not take BRINTELLIX if you:
oAre allergic to vortioxetine or any of the ingredients in BRINTELLIX
oTake a Monoamine Oxidase Inhibitor (MAOI). Ask your healthcare provider or
pharmacist if you are not sure if you take an MAOI, including the
antibiotic linezolid; do not take an MAOI within 21 days of stopping
BRINTELLIX; do not start BRINTELLIX if you stopped taking an MAOI in the
last 14 days
BRINTELLIX may cause serious side effects including:
Serotonin Syndrome: A potentially life-threatening problem that can happen
when medicines such as BRINTELLIX are taken with certain other medicines.
Symptoms may include agitation, hallucinations, coma or other changes in
mental status; problems controlling movements or muscle twitching, stiffness
or tightness; fast heartbeat, high or low blood pressure; sweating or fever;
nausea, vomiting or diarrhea.
Abnormal bleeding or bruising: BRINTELLIX and other serotonergic
antidepressant medicines may increase your risk of bleeding or bruising,
especially if you take the blood thinner warfarin (Coumadin®, Jantoven®), a
non-steroidal anti-inflammatory drug (NSAID), or aspirin.
Manic episode: Symptoms may include greatly increased energy; severe trouble
sleeping; racing thoughts; reckless behavior; unusually grand ideas; excessive
happiness or irritability; talking more or faster than usual.
Low salt (sodium) levels in the blood: Symptoms may include headache;
difficulty concentrating, memory changes or confusion; weakness and
unsteadiness on your feet; and in severe or sudden cases hallucinations,
fainting, seizures or coma. If not treated, severe low sodium levels can cause
Before starting BRINTELLIX, tell your healthcare provider if you have or had
liver problems, seizures or convulsions, bipolar disorder (manic depression)
or mania, low salt (sodium) levels in your blood, bleeding problems, drink
alcohol, have any other medical conditions or if you are pregnant, nursing,
plan to become pregnant, or plan to nurse.
BRINTELLIX and some medicines may interact with each other, may not work as
well, or may cause serious side effects when taken together. Tell your
healthcare provider if you plan on or are taking any other prescription and
non-prescription medicines, vitamins and herbal supplements including
medicines for migraine headaches, such as triptans; medicines used to treat
mood, anxiety, psychotic or thought disorders such as tricyclics, lithium,
SSRIs, SNRIs, bupropion, buspirone or antipsychotics; MAOIs including
linezolid (a specific antibiotic); over-the-counter supplements such as
tryptophan or St. John's wort; and the following medicines: aspirin, NSAIDs,
warfarin (Coumadin®, Jantoven®), diuretics, rifampicin, carbamazepine,
phenytoin, quinidine, tramadol or fentanyl.
Common side effects of BRINTELLIX include: nausea, constipation or vomiting.
These are not all the possible side effects of BRINTELLIX.
Do not start or stop taking BRINTELLIX without talking to your healthcare
provider first. Suddenly stopping BRINTELLIX when you take higher doses may
cause you to have side effects including headache, stiff muscles, mood swings,
sudden outbursts or anger, dizziness or feeling lightheaded, or runny nose.
Until you know how BRINTELLIX affects you, do not drive, operate heavy
machinery or engage in other dangerous activities.
Avoid drinking alcohol while taking BRINTELLIX.
Talk to your healthcare provider.
You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information and Medication Guide for BRINTELLIX.
The Science of Major Depression
The monoamine-deficiency theory posits that the underlying pathophysiological
basis of depression is a depletion of serotonin, norepinephrine or dopamine in
the central nervous system. The exact cause of MDD is unknown. Research
suggests that there are multiple serotonin receptors that may be important in
MDD and may influence many biologic and neurologic processes. The release of
bio-chemicals, such as serotonin, dopamine and norepinephrine enables impulses
to be passed from one cell to another in the nervous system.
Takeda and Lundbeck Alliance
In September 2007, Lundbeck and Takeda Pharmaceutical Company Limited formed a
strategic alliance for the exclusive co-development and co-commercialization
in the U.S. and Japan of several compounds in Lundbeck's pipeline for the
treatment of mood and anxiety disorders. The companies co-promote Brintellix
in the U.S. The Lundbeck–Takeda alliance in the U.S. benefits from the synergy
of Lundbeck's longstanding expertise and knowledge of psychiatry and Takeda's
understanding and established presence in the very important primary care
About Patient Assistance
Healthcare providers and patients may call 1-800-830-9159 to learn more or
obtain application forms for the Help at Hand program, a Patient Assistance
Program to help qualified patients who may benefit from Brintellix gain access
to this therapy without financial barriers.
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
specialized in brain diseases. For more than 50 years, we have been at the
forefront of research within neuroscience. Our development and distribution of
pioneering treatments continues to make a difference to people living with
brain diseases. Our key areas of focus are alcohol dependence, Alzheimer's
disease, depression/anxiety, epilepsy, Huntington's disease, Parkinson's
disease, schizophrenia and stroke. Lundbeck's U.S. business is based in
Deerfield, Illinois. To learn more about Lundbeck in the U.S., visit
Our approximately 6,000 employees in 57 countries are engaged in the entire
value chain throughout research, development, production, marketing and sales,
and are committed to improving the quality of life of people living with brain
diseases. Our pipeline consists of several late-stage development programs and
our products are available in more than 100 countries. We have research
centers in China, Denmark and the United States, and production facilities in
China, Denmark, France, Italy and Mexico. Lundbeck generated revenue of
approximately DKK15 billion in 2012 (EUR 2 billion; USD 2.7 billion).
Lundbeck's shares are listed on the stock exchange in Copenhagen under the
symbol "LUN." Lundbeck has a sponsored Level 1 ADR program listed in the US
(OTC) under the symbol "HLUYY." For additional information, we encourage you
to visit our corporate site www.lundbeck.com.
About Takeda Pharmaceutical Company
Located in Osaka, Japan, Takeda is a research-based global company with its
main focus on pharmaceuticals. As the largest pharmaceutical company in Japan
and one of the global leaders of the industry, Takeda is committed to strive
towards better health for patients worldwide through leading innovation in
medicine. Additional information about Takeda is available through its
corporate website, www.takeda.com.
About Takeda Pharmaceuticals U.S.A., Inc. and Takeda Development Center
Based in Deerfield, Ill., Takeda Pharmaceuticals U.S.A., Inc. and Takeda
Development Center Americas, Inc. are subsidiaries of Takeda Pharmaceutical
Company Limited, the largest pharmaceutical company in Japan. The respective
companies currently market oral diabetes, CNS, rheumatology, gastroenterology
and cardiovascular disease treatments and seek to bring innovative products to
people through a pipeline that includes compounds in development for diabetes,
gastroenterology, neurology and other conditions. To learn more about these
Takeda companies, visit www.takeda.us.
This press release contains forward-looking statements. Forward-looking
statements include statements regarding Takeda's plans, outlook, strategies,
results for the future, and other statements that are not descriptions of
historical facts. Forward-looking statements may be identified by the use of
forward-looking words such as "may," "believe," "will," "expect," "project,"
"estimate," "should," "anticipate," "plan," "assume," "continue," "seek," "pro
forma," "potential," "target," "forecast," "guidance," "outlook" or "intend"
or other similar words or expressions of the negative thereof. Forward-looking
statements are based on estimates and assumptions made by management that are
believed to be reasonable, though they are inherently uncertain and difficult
to predict. Investors are cautioned not to unduly rely on such forward-looking
Forward-looking statements involve risks and uncertainties that could cause
actual results or experience to differ materially from that expressed or
implied by the forward-looking statements. Some of these risks and
uncertainties include, but are not limited to, (1) the economic circumstances
surrounding Takeda's business, including general economic conditions in Japan,
the United States and worldwide; (2) competitive pressures and developments;
(3) applicable laws and regulations; (4) the success or failure of product
development programs; (5) actions of regulatory authorities and the timing
thereof; (6) changes in exchange rates; (7) claims or concerns regarding the
safety or efficacy of marketed products or product candidates in development;
and (8) integration activities with acquired companies.
The forward-looking statements contained in this press release speak only as
of the date of this press release, and Takeda undertakes no obligation to
revise or update any forward-looking statements to reflect new information,
future events or circumstances after the date of the forward-looking
statement. If Takeda does update or correct one or more of these statements,
investors and others should not conclude that Takeda will make additional
updates or corrections.
Ashleigh Duchene Roseanne Durril
Public Affairs Corporate Communications
Lundbeck US Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceutical Company Limited
Corporate Communications Dept.
SOURCE Takeda Pharmaceutical Company Limited
Press spacebar to pause and continue. Press esc to stop.